Xianqiong Lei
Research Subjects
Research Interests
Xianqiong Lei has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Donghu Zhen
Department of Endocrinology (H.Y., M.Y., D.Z.), The First Hospital of Lanzhou University, China
1 shared publication - Hongtao Yin
Department of Endocrinology (H.Y., M.Y., D.Z.), The First Hospital of Lanzhou University, China
1 shared publication Mengdi Yang
The First Clinical Medical College, Lanzhou University, China (R.Z., M.Y.).
1 shared publication- Ruixing Zhang
The First Clinical Medical College, Lanzhou University, China (R.Z., M.Y.).
1 shared publication - Zheng Zhang
Department of Cardiology, The First Hospital of Lanzhou University, Lanzhou, China
1 shared publication
Latest Publications
- 1 November 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (11) , 2255-2264
Advanced Progress of the Relationship Between Antihypertensive Drugs and Bone Metabolism
Hypertension and osteoporosis are common comorbidities among elderly individuals. Drug therapy has been widely used in clinical practice as the preferred antihypertensive treatment. Therefore, antihypertensive drugs have become some of the most commonly prescribed drugs in healthcare settings. However, antihypertensive drugs have different effects on bone metabolism. The results of animal and clinical studies on the effects of antihypertensive drugs on osteoporosis or fracture risk are controversial and have aroused widespread concern among clinicians. Recent studies found that angiotensin receptor blockers, selective β-adrenergic receptor blockers, and thiazide diuretics might improve bone trabecular number and bone mineral density by stimulating osteoblast differentiation, reducing osteoclast generation, and other mechanism. Furthermore, nonselective β-adrenergic receptor blockers and dihydropyridine calcium channel blockers were found to have no significant relationship with bone mineral density or bone strength, and α-adrenergic receptor blockers and loop diuretics might increase fracture risk by decreasing bone mineral density. This article aimed to review previous animal experiments, clinical studies, and meta-analyses focusing on the effects of different antihypertensive drugs on bone metabolism, and to provide a new approach for the prevention and treatment of osteoporosis.
- 1 November 2023
- Published by Wolters Kluwer Health in Hypertension
- Vol. 80 (11) , 2255-2264
Advanced Progress of the Relationship Between Antihypertensive Drugs and Bone Metabolism
Hypertension and osteoporosis are common comorbidities among elderly individuals. Drug therapy has been widely used in clinical practice as the preferred antihypertensive treatment. Therefore, antihypertensive drugs have become some of the most commonly prescribed drugs in healthcare settings. However, antihypertensive drugs have different effects on bone metabolism. The results of animal and clinical studies on the effects of antihypertensive drugs on osteoporosis or fracture risk are controversial and have aroused widespread concern among clinicians. Recent studies found that angiotensin receptor blockers, selective β-adrenergic receptor blockers, and thiazide diuretics might improve bone trabecular number and bone mineral density by stimulating osteoblast differentiation, reducing osteoclast generation, and other mechanism. Furthermore, nonselective β-adrenergic receptor blockers and dihydropyridine calcium channel blockers were found to have no significant relationship with bone mineral density or bone strength, and α-adrenergic receptor blockers and loop diuretics might increase fracture risk by decreasing bone mineral density. This article aimed to review previous animal experiments, clinical studies, and meta-analyses focusing on the effects of different antihypertensive drugs on bone metabolism, and to provide a new approach for the prevention and treatment of osteoporosis.